Erratum: "Preoperative systemic treatment: Prediction of responsiveness" (The Breast (2003) vol. 12(6) (538-542) 10.1016/S0960-9776(03)00163-2);Preoperative systemic treatment: Prediction of responsiveness

Breast

Volumn 12, Issue 6, 2003, Pages 538-542

  Colleoni, Marco ^a   Zarieh, D ^b   Gelber, R D ^b   Viale, G ^a   Luini, A ^a   Veronesi, P ^a   Intra, M ^a   Galimberti, V ^a   Renne, G ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

Breast cancer; Predictive factors; Preoperative therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE; KI 67 ANTIGEN; LETROZOLE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROGESTERONE RECEPTOR; TAMOXIFEN; THIOTEPA; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG USE; FEMALE; GENE OVEREXPRESSION; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; TUMOR BIOPSY; TUMOR VOLUME;

EID: 0346600381     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.01.001     Document Type: Erratum

References (21)

1. Fisher B, Gunduz N, Saffer E A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 1983; 43:1488-1492.
2. Fisher B, Gunduz N, Coyle J et a]. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
3. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
4. Semiglazov V F, Topuzov E E, Bavli J L et al. Primary (neo-adjuvant) chemotherapy and radiotherapy compared with primary radio-therapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994; 5: 591-595.
5. Scholl S M, Pierga J Y, Asselain B et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995; 31A: 1969-1975.
6. Powles T J, Hickish T F, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
7. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
8. Ragaz J, Baird R, Rebbeck P et al. Preoperative (neoadjuvant-PRE) versus postoperative (POST) adjuvant chemotherapy (CT) for stage I-II breast cancer (SI-II BC): long term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 1997; 16: 499.
9. Jakesz R. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group Trial 7. Proc Am Soc Clin Oncol 2001; 20: 125.
10. Van der Hage J A, Van de Velde C J H, Julien J P et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.
11. Goldhirsch A, Glick J H, Gelber R D et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
12. NSABP. The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treatment 2001; 69: 5.
13. Smith I C, Heys S D, Hutcheon A W et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
14. Fisher E R, Wang J, Bryant J et al. Pathobiology of preoperative chemotherapy findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. Cancer 2002; 95: 681-695.
15. Kiang D T, Frenning D H, Goldman A I et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 1978; 299: 1330-1334.
16. Lippman M E, Allegra J C. Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer? Recent Results Cancer Res 1980; 71: 155-61.
17. Colleoni M, Minchella I. Mazzarol G et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesteron receptors. Ann Oncol 2000; 11: 1-3.
18. MacGrogan G, Mauriac L, Durand M et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immuno-histochemical detection of hormonal receptors, p53, c-erbB-2. MiB1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-1465.
19. Sorlie T, Perou C M, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
20. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 5979-5984.
21. Sataloff D M, Mason B A, Prestipino A J. Pathological response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-304.